<DOC>
	<DOC>NCT01207414</DOC>
	<brief_summary>Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.</brief_summary>
	<brief_title>Switching to Iloperidone From Other Antipsychotics in Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Males or females, 18 to 64 years of age, inclusive DSMIV diagnosis of schizophrenia Patients currently on an optimal inlabel dose of one of the following permitted antipsychotic treatments for at least 30 days: risperidone, olanzapine, or aripiprazole Efficacy Clinical Global Impression of Severity (ECGIS) of 4 or 5 or Not tolerating one of the permitted treatments and exhibits one of the allowable sideeffects Any other current Axis I disorder other than schizophrenia which is the focus of treatment; Acutely psychotic or patient's symptom severity requires hospitalization Patient with significant cardiovascular illness (myocardial infarction, cardiac arrhythmia) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>iloperidone</keyword>
	<keyword>switch</keyword>
	<keyword>gradual switch</keyword>
	<keyword>immediate switch</keyword>
</DOC>